Innovation Pharmaceuticals Inc. is a biopharmaceutical company founded to develop innovative medical therapies targeting a range of conditions, including cancer, rheumatoid arthritis, asthma, and autism. The company's core mission is to advance the fight against infectious diseases and debilitating side effects of treatments like chemoradiation. Their flagship product, Brilacidin, is a small molecule mimetic of defensins with broad-spectrum antimicrobial and immunomodulatory properties. Innovation Pharmaceuticals focuses on leveraging the body's natural defense mechanisms to create effective treatments.

Notable affiliated individuals include the company's founders and key scientists who have contributed to the development of their drug candidates. The company has garnered attention from investors due to its promising pipeline and the Fast Track designation granted to Brilacidin by regulatory authorities. Key achievements include advancing Brilacidin through various stages of clinical trials and demonstrating its potential in treating multiple conditions. Overall, Innovation Pharmaceuticals has made a significant impact in the biopharmaceutical industry by pushing forward novel therapies that address unmet medical needs.